Division of Amgen Inc.
Latest From CancerVax Corp.
Appointments: Merck KGaA, Myovant, Scholar Rock, C4X Discovery, Paragon Bioservices and Gamida Cell.
This week's roundup includes appointments by Merck KGaA, C4X Discovery Holdings, Paragon Bioservices and board appointments by Scholar Rock, Myovant Sciences and Gamida Cell.
Eventually, someone is going to have clinical and commercial success with a personalized cancer therapy. Learning from the mistakes of Dendreon and others, Argos Therapeutics expects to be first, and automation is its key.
Reverse mergers like Micromet's takeover of Cancervax and Cyclacel's takeover of Xcyte Therapies illustrate both tough times for IPO contenders as well as the innovative and sometimes win-win solution a reverse merger can provide.
New approaches to cancer immunotherapy promise to change the face of cancer care in a way that will reverberate through the field for years to come. In this issue, we profile Borean Pharma, OncoMed Pharmaceuticals and Receptor Logic.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Amgen Inc.
- Senior Management
David F Hale, Pres. & CEO
William R LaRue, SVP, CFO
Martin Mattingly, EVP, Mktg. & Bus. Dev.
Dennis E Van Epps, VP, Research
- Contact Info
Phone: (760) 494-4200
2110 Rutherford Rd.
Carlsbad, CA 92008